UC BON.CAP.CERT. 12/24 LLY/ DE000HD6QCV2 /
2024-08-07 9:00:25 AM | Chg.- | Bid9:16:37 AM | Ask- | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
783.770EUR | - | 783.470 Bid Size: 10,000 |
- Ask Size: - |
ELI LILLY | - - | 2024-12-31 | Call |
GlobeNewswire
07-01
Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studyi...
GlobeNewswire
06-28
Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combin...
GlobeNewswire
06-21
HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
GlobeNewswire
06-19
Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors
GlobeNewswire
06-12
US Gastroenterologists Express Anticipation for Approval of AbbVie’s Skyrizi in Ulcerative Colitis, ...
GlobeNewswire
06-11
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D ...
GlobeNewswire
06-11
Skyhawk Therapeutics Promotes Clint Musil to Chief Executive Officer and Appoints Co-founder Bill Ha...
GlobeNewswire
06-11
Adverum Biotechnologies Announces Appointments of Dr. Rabia Gurses Ozden as Chief Medical Officer an...
GlobeNewswire
06-11
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next...
GlobeNewswire
06-10
Sermonix Pharmaceuticals Announces Breast Cancer Research Publication of Paper Examining Lasofoxifen...